Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded from 85 to 91 Monday.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength. This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating of over 80 as they begin their largest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Vir Biotechnology Stock A Buy?
Vir Biotechnology stock is currently living under 200-day moving average and not near a potential buy zone. See if the stock goes on to build a sound pattern that could kick off a new price move. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 391%. Revenue rose from 46,880% to 62,145%. The company is expected to report its latest performance numbers on or around Aug. 5.
Vir Biotechnology stock holds the No. 12 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls, Corcept Therapeutics and Dynavax Technologies are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
